Quick Take: Revive Therapeutics, a company focused on R&D of therapeutics for medical needs and rare disorders, announced that they received U.S. Food & Drug Administration approval to proceed with the company’s Phase 3 clinical trial to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19 Revive also plans to explore FDA…